Compare GSK plc (GSK) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Sony Group Corp — how do they compare? GSK plc trades at $50.29 (market cap $102.60B), while Sony Group Corp trades at $23.51 (market cap $138.43B). The key difference: Sony Group Corp is the larger of the two by market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | SONY | |
|---|---|---|
Market Cap | $102.60B | $138.43B |
Sector | Health | Technology |
52-Week High | $61.18 | $30.26 |
52-Week Low | $38.22 | $19.32 |
Enterprise Value | $123.04B | $136.35B |
Dividend Yield | 3.57% | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Sony's stock is trading at $23.48, down 1.43% over the past day, with a bullish technical outlook supported by moving averages. The company reported strong cash flow of $1.07 trillion in 2025 and beat EPS estimates in two of the last three quarters, though Q1 2026 was a miss. Recent news highlights success from Spider-Man: Brand New Day and a joint venture with TSMC for image sensors, signaling growth in entertainment and technology segments.
The investment outlook is positive, driven by analyst consensus favoring a buy rating (68.75%) and potential upside from blockbuster films and sensor innovation. Key risks include a projected net loss in 2026, competitive pressures in gaming, and currency volatility. Fundamentals show solid revenue but margin compression, requiring careful monitoring of profit trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
